By Mar. 2022, most U.S. state clinical laboratories were aware of revised equations for estimating glomerular filtration rates (eGFRs) as adopted in Sept. 2021 by
In a collaborative meta-analysis of large placebo-controlled trials, SGLT2 inhibitors had beneficial effects on patients with chronic kidney disease or heart failure irrespective of diabetes
Lancet: Challenges and Opportunities for Educating Health Professionals After the COVID-19 pandemic Diabetes Care: Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of
Duration of steroid treatment protocols for children with newly diagnosed idiopathic nephrotic syndrome could possibly be adjusted based on clinical response, a study shows, lowering
A scientific workshop of 90 stakeholders in nephrology, clinical trials, and other fields convened virtually in Dec. 2020 to discuss the validation of surrogate end
The pathogenesis, precipitating events, clinical presentations, diagnoses, and treatments of metabolic alkalosis are reviewed in an AJKD Core Curriculum 2022 article. “Severe metabolic alkalosis in
Many patients with type 2 diabetes (T2D) who are at increased risk of chronic kidney disease (CKD) do not receive renoprotective therapy with SGLT2 inhibitors
FDA has approved the vasopressin receptor agonist terlipressin (Terlivaz, Mallinckrodt) injection to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney